

November 2, 2020

Listing Department

BSE LIMITED

P J Towers, Dalal Street, Fort,

Mumbai-400 001

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai-400 051

Re:

Outcome of Board Meeting

Dear Sir,

The Board of Directors at their meeting held today i.e. November 2, 2020, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter / half year ended on September 30, 2020.

Code: 531335

Code: ZYDUSWELL

In this regard, please find enclosed the following:

- the unaudited financial results (standalone and consolidated) for the quarter / half year ended on September 30, 2020, reviewed by the Audit Committee and taken on record by the Board of Directors pursuant to regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015 ("the Listing Regulations").
- 2. the Limited Review Reports of Mukesh M. Shah & Co., Chartered Accountants, the Statutory Auditors of the Company certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter / half year ended on September 30, 2020 pursuant to regulation 33 of the Listing Regulations.
- 3. press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter / half year ended on September 30, 2020.
- The Trading Window under SEBI Insider Trading Regulations, 2015 shall remain closed for trading till November 4, 2020 and shall reopen from November 5, 2020 for the Directors and Designated Persons.
- The Board Meeting commenced at 10.15 a.m. and concluded at 11.25 a.m.





Please receive the information and disclosures in order.

Thanking you,

Yours faithfully,

For, ZYDUS WELLNESS LIMITED

DHANRAJ P. DAGAR COMPANY SECRETARY

Encl.: As above

Zvdus			Reg	istered office : 2)			Zydus Wellness Limited eme No. 63, Survey No. 536 Khora) (Gandhinagar), Nr. Vaishnodevi Circle,		hmedabad 382 4	181.			
Zydus Wellness) 4804 0000 Website: www.zyduswellness.in, CIN No: L15201GJ1994PL audited Results for the Quarter and Six Months Ended September						
110000000000000000000000000000000000000		₹ in	Lakhs		Stateme	nt or or	ludited Results for the Quarter and six Profitus Ended Copsonio	30, 2020		₹in L	akhs		
			LIDATED							COMP			
- 0	Ouarter Ende	d	Six Mont	ths Ended	Year Ended		8.5		Quarter Ended		Six Mont	ths Ended	Year Ende
September	June	September	September	September	March	Sr. No.	Particulars	September	June	September	September	September	March
30,2020	30, 2020	30, 2019	30, 2020	30, 2019	31, 2020		X ii	30,2020	30, 2020	30, 2019	30, 2020	30, 2019	31, 2020
Unaudited1	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited]			[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited
	Lunca	14.102	Land			1	Revenue						
	1					a	Revenue from operations	1	(388)		1.000.00	88.500	59500
34,032	53,618	31,729	87,650	92,371	1,73,419	ı.	Sales	2,267	1,068	3,958	3,335	7,641	15,3
167	119	874	286	2,257	3,263	н.	Other operating income	48	12	5	60	14	
281	182	395	463	698	1,071	b	Other income	2,729	2,632	2,661	5,361	5,266	10,9
34,480	53,919	32,998	88,399	95,326	1,77,753		Total Revenue	5,044	3,712	6,624	8,756	12,921	26,2
			1/16/2004	173835555	V2823800-0	2	Expenses		0.00	2.20	100000000000000000000000000000000000000		
13,356	10,945	10,619	24,301	23,545	75,382	a	Cost of materials consumed	1,329	495	2,418	1,824	4,610	9,8
1,277	4,027	559	5,304	3,908	8,249	b	Purchases of stock-in-trade			15		38	1
	58 (88%)	SALESSEE.	See See	579624		c	Changes in inventories of finished goods, work-in-progress and	2500	1222	42472	1222		
1,210	8,858	2,945	10,068	11,965	(5,754)	500	stock-in-trade	187	208	(231)		(269)	(6
4,301	4,243	3,838	8,544	7,662	15,601	d	Employee benefits expense	864	833	792	1,697	1,663	3,1 14,0
3,083	3,460	3,511	6,543	6,996	13,991	e	Finance costs	3,488	3,463	3,558	6,951	7,119	
649	642	382	1,291	1,417	2,639	f	Depreciation and amortisation expense	87	82 98	66 109	169 449	129. 452	2 5
5,065	4,914	5,426	9,979	14,704	22,426	9	Advertisement and promotion expenses	351 919	98 877	1,163	1,796	2,331	4,2
6,278	8,515	6,171	14,793	14,928	28,672	h	Other expenses	7,225	6,056	7,890	13,281	16,073	31.75
35,219	45,604	33,451	80,823	85,125	1,61,206	3	Total expenses			(1,266)			
(739)	8,315	(453)	7,576	10,201	16,547		Profit/(Loss) before exceptional items and tax(1-2)	(2,181)	(2,344)	(1,266)	(4,525)	(3,152)	(5,4
9,795		1,005	9,795	3,675	4,420	4	Exceptional items	(2,181)	(2,344)	(1,266)	(4,525)	(3,152)	(5,4
(10,534)	8,315	(1,458)	(2,219)	6,526	12,127	5	Profit/ (Loss) before tax (3-4)	(2,181)	(2,394)	(1,200)	(4,525)	(3,152)	(5,4
		54	1970		(nee)		Tax expense Current tax	100	589	983	1000	1947	7/2
•	(605)	(256)	(605)	(312)	(265) (1,780)	a	Deferred tax	1 1	(599)	(18)	(599)	(28)	(1,4)
<u> </u>	(605)	(256)	(605)			D	Total tax expenses		(599)	(18)			
(10,534)	8,920	(1,202)	(1,614)		14,172	7	Net Profit (5-6)	(2,181)	(1,745)		(3,926)		(4,0)
(10,534)	8,920	(1,202)	(1,014)	0,030	14,172	Ŕ	Other Comprehensive Income (OCI)	(2,202)	(2,713)	(1,2 10)	(3,520)	(0,12.1)	(1,0
(14)	25	19	11	14	201	ı a	Items that will not be reclassified to profit or loss (net of tax)	(18)	(7)	(22)	(25)	(32)	(
(11)	(1)	12	(12)		17	l š	Items that will be reclassified to profit or loss (net of tax)	(20)		,/	1 -		1
(25)	24	19	(1)		218		Other Comprehensive Income (OCI)	(18)	(7)	(22)	(25)	(32)	1
(10,559)	8,944	(1,183)	(1,615)		14,390	9	Total Comprehensive Income (7+8)	(2,199)		(1,270)			
(10,539)	0,241	(1,203)	(1,515)	0,032	2,,550	10	Total Comprehensive Income attributable to:	(-,222)	(-,,52)	(-,2,0)	,,,,,,,,,	1	1 ,,,,
(10,559)	8.944	(1,183)	(1,615)	6,852	14,390	a	Owners of the company	(2,199)	(1,752)	(1,270)	(3,951)	(3,156)	
6,363	5,766	5,766	6,363	5,766	5,766	11	Paid-up equity share capital (Face Value ₹ 10 each)	6,363	5,766	5,766	6,363	5,766	5,7
3,000	3,700	5,700	0,505	1	3,40,300	12	Reserve excluding Revaluation Reserve	1		13866.0	0.4000	10,85000	3,15,7
	l .				37,500	13	Debenture Redemption Reserve	1		l		1	37,5
	1			1	72,677.00	14	Earnings per share [EPS]	1		1		1	1201000
						14	[EPS for quarter and six months ended is not annualized]					1	1
(18.14)	15.47	(2.09)	(2,79)	11.86	24.58	a	Basic (₹)	(3.76)	(3.03)	(2.16)			
(18.14)		(2.09)	(2.79)		24.58	b	Diluted (₹)	(3.76)	(3.03)	(2.16)			
3000			0.35	0.44	0.44	15	Debt Equity Ratio		111111111		0.37	0.46	
	1		0.04	1.93	1.87	16	Debt Service Coverage Ratio				0.35		
	1		0.66	1.93	1.87	17	Interest Service Coverage Ratio				0.35	0.56	0

1 The above financial results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on November 2, 2020. The Statutory auditors of the Company have expressed unmodified opinion on the aforesaid result. 2 The Statutory Auditors of the Company have carried out a "Limited Review" of the above financial results pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
3 The Company had issued Secured Redefemable Non-Convertible Debendures (NCDs) of ₹ 150,000 lakts. These NCDs have been secured by way of charge on specific brands. The asset cover of the said NCDs as on September 30, 2020 exceeds hundred percent of the principal amount of the NCDs. The Company obtained long term credit rating for issuance of NCDs and was assigned credit ratings of "CRISIL United and "CARE AA+/ Stable" from CRISIL United and "CARE AA+/ Stable" from CARE Rating Limited. There is no change in the ratings of the NCDs by any of the rating advanced solving the quarters.
5 Due to seasonality of some of the Group's products, Group's Revenues and Profits are skewed in favour of the first and last quarters of the financial year, Hence the performance of these quarters is not representative and cannot be generalised for other quarters.

5 Due to assorbality of some of the Group's products, Group's Revenues and Profits are skewed in favour of the first and last quarters of the financial year, Hence the performance of these quarters is not representative and cannot be generalised for other quarters.

6 The Company has issued and allotted 21,22,000 and 38,46,000 Equity Shares of ₹ 10 each to Promotors group and Qualified Institutional Placement on September 19, 2020 and September 28, 2020 at an issue price of ₹ 1,649 and ₹ 1,659 per Equity Shares in Fromotors group and Qualified Institutional Placement, the paid up share capital of the Company stands Increased to ₹ 6,363 Lakhs.

7 Exceptional times: a) In the process of integrations and conducting the merger of the acquired entity, Company increased wards transition service agreement (TSA), consultancy feet, stamp duties, legal and professional charges and other incidental charges. The Company would not have incurred these expenses in the normal course of business and hence these expenses are classified as Exceptional items for the quarter and six months ended September 30, 2019, and year ended March 31, 2020. b) The Secured Non-Converbible debentures (NCD) that were previously issued by the Company have been from the market aggregating to ₹ 1,10,500 lakher during the quarter ending September 30, 2020 and read held by the subsidiary Company as a September 30, 2020 and an exceptional items in the aforesaid results.

8 As per the current assessment of the situation based on the internal and external Information available up to the destination and the company control or forectors, the Company control to Exceptional Items in the aforesaid results.

8 As per the current assessment of the situation based on the internal and external Information available up to the destination and the company control or forectors, the Company control to Exceptional Items in the aforesaid results.

8 As per the current assessment of the situation based on the internal and external Information available up to the destinat

		Balance Sheet			
₹ in La	khs			₹ in L	
CONSOLI	DATED	Si and the second secon		COMP	ANY
As a	it	Particulars		As	at
September	March	rai ticulais		September	March
30, 2020	31, 2020			30, 2020	31, 2020
[Unaudited]	[Audited]			[Unaudited]	[Audited]
		ASSETS:			
		Non-current assets:		san allen	A value
18,355	18,877	Property, plant and equipment		2,020	1,913
1,570	1,590	Right-of-use assets	2	69	77
422	353	Capital work-in-progress		62	147
3,92,002	3,92,002	Goodwill	- 1	2,282	2,282
54,903	54,883	Other intangible assets		-	
	*	Financial assets:	- 1	en een mesen	
•		Investments	- 1	3,47,126	3,52,758
-	-	Loan	- 1	1,12,129	1,12,136
971	977	Other financials assets	- 1	46	51
982	465	Other non-current assets	- 1	730	264
12,684	12,079	Deferred tax assets [net]	- 1	1,998	1,399
-	163	Assets for tax [net]	L	276	485
4,81,889	4,81,389	Total Non Current Assets	- 1	4,66,738	4,71,512
and wages	252 55127	Current assets:	0		
20,039	29,234	Inventories	- 1	901	1,234
	eserce approprie	Financial assets:	- 1		
35,017	11,041	Investment	- 1	35,017	
9,296	11,820	Trade receivables	- 1	230	55
8,701	5,448	Cash and cash equivalents	- 1	1,050	193
77,941	2,794	Bank balance other than cash and cash equivalents	- 1	71,907	2,787
-	-	Other current financial assets		2,571	2,542
15,423	17,242	Other current assets	-	2,179	1,953
1,66,417	77,579	Total Current Assets	-	1,13,855	8,764
6,48,306	5,58,968	Total Assets	-	5,80,593	4,80,276
		EQUITY AND LIABILITIES:			
	F 766	Equity:	-21	6 262	F 766
6,363	5,766	Equity share capital	.x	6,363 4,09,823	5,766 3,15,704
4,36,754	3,40,300	Other equity	-	4,16,186	3,21,470
4,43,117	3,46,066	Total Equity Liabilities:	- 1	4,10,100	3,21,470
1		Non-current liabilities:			
		Financial liabilities:	- 1		
0 00	1,50,000	All the state of t	- 1	_	1,50,000
57	1,50,000	Borrowings Lease liabilities		57	1,30,000
44	51	Other financial liabilities		42	45
2,775	2,437	Provisions	1	302	194
134	168	Other non-current liabilities		-	
3,010	1,52,720	Total Non Current Liabilities	- 1	401	1,50,303
3,010	1,52,720	Current liabilities:	t	,,,,	2/00/000
		Financial liabilities:	- 1		
1,15,544	1,905	Borrowings		5,544	1,630
2,23,514	1,505	Trade payables	- 1	-,	-,-30
797	654	Due to micro and small enterprises		13	10
37,626	48,458	Due to other than micro and small enterprises		4,533	3,287
15	14	Lease liabilities	- 1	15	14
42,666	4,277	Other financial liabilities	- 1	1,53,409	3,198
3,247	3,390	Other current liabilities	- 1	370	281
2,244	1,484	Provisions	1	122	83
40	-	Current tax liabilities [net]		-	_
2,02,179	60,182	Total Current Liabilities	ı	1,64,006	8,503
		Total Equity & Liabilities	- t	5,80,593	4,80,276

		Statement of Cash Flow		
₹ in Lakhs	akhs		₹ in Lakhs	akhs
CONSOLIDATED	IDATED		COMPANY	ANY
Six Months Ended	is Ended		Six Months Ended	s Ended
September	September	raiticulais	September	September
30, 2020	30, 2019		30, 2020	30, 2019
[Unaudited]	[Unaudited]		[Unaudited]	[Unaudited]
		Cash flow from operating activities:		
7,576	10,201	Profit/(Loss) before exceptional items and tax	(4,525)	(3,152)
14,946	14,256	Operating Profit before working capital changes	(2,766)	(1,170)
17,433	19,738	 A. Net cash from/ (used in) operating activities 	(2,937)	(757)
(242)	(173)B.	B. Net cash from/ (used in) investing activities	10,939	16,419
85,185	(16,647) C.	C. Net cash from/ [used in] financing activities	96,992	(16,770)
1,02,376	2,918	Net increase in cash and cash equivalents (A+B+C)	1,04,994	(1,108)
		Cash and cash equivalents *		
19,283	21,039	At the beginning of the period	2,980	4,298
1,21,659	23,957	At the end of the period	1,07,974	3,190
* Cash and cash	l equivalents inc	* Cash and cash equivalents includes cash and cash equivalents, Bank balance other than cash and cash equivalents and Investments in liquid	ts and Investment	s in liquid
			By Orde	By Order of the Board,
24			For Zydus We	For Zydus Wellness Limited,
			<	
				28
			~	
22			A P	2
Place: Ahmedabad Date: November 2, 2020	ad r 2, 2020		, Ď	r. Sharvil P. Patel Chairman

7th Floor, Heritage Chambers B/h. Bikanerwala, Off S.M. Road, Nr. Azad Society, Nehru Nagar, Ahmedabad-380 015.

Phone : (B) 079 - 2647 2000 E mail : contact@mmsco.in

Website: www.mmsco.in



AHMEDABAD • MUMBAI • BANGALORE

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Zydus Wellness Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors, Zydus Wellness Limited Ahmedabad

- 1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Zydus Wellness Limited ['the Company'], for the quarter and six months ended on September 30, 2020 ['the Statement'] attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 as amended by SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019.
- 2. This statement, which is the responsibility of the Company's Management and approved by Company's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Ind-AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

, Heritage

Nehru Nagar, Ambawadi, Ahmedabad-1

Place: Ahmedabad

Date: November 2, 2020

UDIN: 20030190AAAAAG7671

For Mukesh M. Shah & Co Chartered Accountants Firm Regn. No. 106625W

Mukesh M. Shah

Partner

Membership No. 030190

7th Floor, Heritage Chambers B/h. Bikanerwala, Off S.M. Road, Nr. Azad Society, Nehru Nagar, Ahmedabad-380 015.

Phone : (B) 079 - 2647 2000 E mail : contact@mmsco.in

Website: www.mmsco.in




Limited Review Report on Unaudited Quarterly Consolidated Financial Results of Zydus Wellness Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To, The Board of Directors, Zydus Wellness Limited Ahmedabad

- 1. We have reviewed the accompanying statement of unaudited Consolidated financial results of Zydus Wellness Limited ['the Parent'] and its subsidiaries [the Parent and its subsidiaries together referred to as 'the Group'] for the quarter and six month ended on September 30, 2020 ['the Statement'] attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 as amended by SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019.
- 2. This statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on this statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the financial results of the following entities:
 - a) Parent Company
 - i) Zydus Wellness Limited
 - b) Subsidiary Companies
 - i) Zydus Wellness Products Limited
 - ii) Liva Nutritions Limited
 - iii) Liva Investments Limited
 - iv) Zydus Wellness International DMCC



7th Floor, Heritage Chambers B/h. Bikanerwala, Off S.M. Road,

Nr. Azad Society, Nehru Nagar, Ahmedabad-380 015. Phone: (B) 079 - 2647 2000 E mail: contact@mmsco.in

Website: www.mmsco.in



AHMEDABAD · MUMBAI · BANGALORE

- 5. Based on our review conducted and procedures performed as stated in Paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind-AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information of a subsidiary included in the consolidated unaudited financial results; whose interim financial information reflect total assets of ₹ 596,382 Lakhs as at September 30, 2020, total revenues of ₹ 32,351 Lakhs and ₹ 84,448 Lakhs for the quarter and six months ended September 30, 2020 respectively, total net loss after tax of ₹ 8,347 Lakhs and ₹ 7,406 Lakhs for the quarter and six months ended September 30, 2020 respectively, total comprehensive loss of ₹ 8,343 Lakhs and ₹ 7,370 Lakhs for the quarter and six months ended September 30, 2020 respectively and net cash inflows of ₹ 1,18,695 Lakhs for the six months ended September 30, 2020, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of the other auditors.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated financial results also include the financial information of three subsidiaries included in the consolidated unaudited financial results; whose interim financial information reflect total assets of ₹ 1,301 Lakhs as at September 30, 2020, total revenues of ₹ 1,013 Lakhs and ₹ 1,835 Lakhs for the quarter and six months ended September 30, 2020 respectively, total net profit after tax of ₹ 70 Lakhs and ₹ 303 Lakhs for the quarter and six months ended September 30, 2020 respectively, total comprehensive loss of ₹ 70 Lakhs and ₹ 303 Lakhs for the quarter and six months ended September 30, 2020 respectively and net cash inflows of ₹ 141 Lakhs for the six months ended September 30, 2020, as considered in the Statement. No limited review of these financial information has been carried out by the auditors of the respective subsidiaries; however, according to the information and explanations given to us by the Management, these interim financial information have been subjected to review by the management of the respective subsidiaries. This interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information as certified by the management.

M. SH

7, Heritage Chambers, Nehru Nagar,

Ambawadi, hmedabad-15

Place: Ahmedabad

Date: November 2, 2020

UDIN: 20030190AAAAAH8405

For Mukesh M. Shah & Co Chartered Accountants Firm Regn. No. 106625W

Mukesh M. Shah

Partner

Membership No. 030190



Piess Release

Press Release

Press Release

Piess Release

Press Release

Press Release

Zydus Wellness Ltd., posts Total Income from operations of Rs. 3420 mn in Q2

Ahmedabad, November 02, 2020

For the second quarter ending September 30, 2020, Zydus Wellness Ltd., reported a growth of 9.3% in Gross Sales. The Total Income from operations was reported at Rs. 3420 million up by 4.9% y-o-y. PBT before exceptional items was down by 63.1% y-o-y to (-) 74 Million Rupees. However, the same was up by 27% before GST budgetary support that ceased for Sitargani plant from January 2020 onwards.

During the quarter, the Company has successfully completed preferential issue and QIP issue of equity shares by raising Rs.3,499 million and Rs.6,500 million respectively from the above issuance, the proceeds of which will be used towards redemption of non-convertible debentures. As a part of strategic initiative to pare down the debt the Company has bought back its own non-convertible debentures of Rs.11,050 million which will help the Company reduce the debt burden and deleverage the balance sheet. In the process of buying back its own Non-convertible debentures, of Rs.11050 million, the Company has paid one-time debenture redemption premium of Rs.980 million which is recorded as an exceptional item in the financials for the quarter.

The completion of buy back of non-convertible debentures will result in lower interest cost and shall have a positive impact on the Earning Per Share (EPS) of the Company over a period of time.

During the quarter gone by, key brands namely, Sugar Free, Everyuth Scrub and Everyuth Peel Off, Glucon D and Nycil continued to hold strong positions in their respective categories.

The company continued to grow the categories and increase market share of its brands with new offerings and expanding its reach through e-commerce channels and building brand advocacy, during the quarter.

Glucon-D ImmunoVolt was launched to tap the heightened need of Immunity products for kids. The product is fortified with Vitamin C, Vitamin D, and Zinc to boost immunity. Complan was launched in an economical and handy 75g Sachet priced at Rs.30 per pack. Sugar Free has seen brisk sales in the e-commerce channel and has grown at more than 100% vs corresponding quarter last year on this channel. The quarter also witnessed the launch of Everyuth Aloe Vera & Cucumber Gel in the face moisturizers segment. The company also launched Nutralite Choco Spread on the e-commerce and modern trade platform. Nutralite Choco Spread is available in two healthier variants - Crunchy Quinoa & Calcium.

###